Page 38 - GHES-3-3

Global Health Economics and
Sustainability
Semaglutide for treating T2D and obesity

Adverse effects of GLP-1 receptor agonists. The Review of and challenges. Nutrients, 15(5):1096.
Diabetic Studies, 11(3-4):202-230.
https://doi.org/10.3390/nu15051096
https://doi.org/10.1900/RDS.2014.11.202
Karagiannis, T., Bekiari, E., & Tsapas, A. (2023). Socioeconomic
Galicia-Garcia, U., Benito-Vicente, A., Jebari, S., Larrea-Sebal, aspects of incretin-based therapy. Diabetologia, 66(10):1859-
A., Siddiqi, H., Uribe, K.B., et al. (2020). Pathophysiology of 1868.
type 2 diabetes mellitus. International Journal of Molecular https://doi.org/10.1007/s00125-023-05962-z
Sciences, 21(17):6275.
Kennedy, C., Hayes, P., Salama, S., Hennessy, M., & Fogacci, F.
https://doi.org/10.3390/ijms21176275
(2023). The effect of semaglutide on blood pressure in
Gallwitz, B. (2019). Clinical use of DPP-4 inhibitors. Frontiers in patients without diabetes: A systematic review and meta-
Endocrinology (Lausanne), 10:389. analysis. Journal of Clinical Medicine, 12(3):772.
https://doi.org/10.3389/fendo.2019.00389 https://doi.org/10.3390/jcm12030772
Gao, X., Hua, X., Wang, X., Xu, W., Zhang, Y., Shi, C., et al. (2022). Lane, P., & Milesi-Ferretti,G.M. (2018). The External Wealth of
Efficacy and safety of semaglutide on weight loss in obese or Nations Revisited: International Financial Integration in the
overweight patients without diabetes: A systematic review Aftermath of the Global Financial Crisis. IMF Economic
and meta-analysis of randomized controlled trials. Frontiers Review. Vol. 66. Palgrave Macmillan: International
in Pharmacology, 13:935823. Monetary Fund, p.189-222.
https://doi.org/10.3389/fphar.2022.935823 https://doi.org/10.1057/s41308-017-0048-y
Garcia-Casares, N., Gonzalez-Gonzalez, G., de la Cruz-Cosme, C., Laursen, H.V.B., Jorgensen, E.P., Vestergaard, P., & Ehlers, L.H.
Garzon-Maldonado, F.J., de Rojas-Leal, C., Ariza, M.J., et al. (2023). A systematic review of cost-effectiveness studies of
(2023). Effects of GLP-1 receptor agonists on neurological newer non-insulin antidiabetic drugs: Trends in decision-
complications of diabetes. Reviews in Endocrine and analytical models for modelling of type 2 diabetes mellitus.
Metabolic Disorders, 24(4): 655-672. Pharmacoeconomics, 41(11):1469-1514.
https://doi.org/10.1007/s11154-023-09807-3 https://doi.org/10.1007/s40273-023-01268-5
Global Health & Population Project on Access to Care for Lee, D.S.U., & Lee, H. (2022). Adherence and persistence rates of
Cardiometabolic Diseases (HPACC). (2021). Expanding major antidiabetic medications: A review. Diabetology and
access to newer medicines for people with type 2 diabetes Metabolic Syndrome, 14(1):12.
in low-income and middle-income countries: A cost-
effectiveness and price target analysis. Lancet Diabetes https://doi.org/10.1186/s13098-022-00785-1
Endocrinology, 9(12):825-836. Ling, J., Chen, S., Zahry, N.R., & Kao, T.A. (2023). Economic
https://doi.org/10.1016/S2213-8587(21)00240-0 burden of childhood overweight and obesity: A systematic
review and meta-analysis. Obesity Reviews, 24(2):e13535.
Gu, Y., Sun, L., Zhang, W., Kong, T., Zhou, R., He, Y., et al. (2023).
Comparative efficacy of 5 sodium-glucose cotransporter https://doi.org/10.1111/obr.13535
protein-2 (SGLT-2) inhibitor and 4 glucagon-like peptide-1 Lv, L., Brady, B.L., Xie, L., Guevarra, M., & Turchin, A. (2024).
(GLP-1) receptor agonist drugs in non-alcoholic fatty liver Adherence and persistence among people with type 2 diabetes
disease: A GRADE-assessed systematic review and network newly initiating oral semaglutide versus DPP-4is in a US real-
meta-analysis of randomized controlled trials. Frontiers in world setting. Primary Care Diabetes, 18(5):511-517.
Pharmacology, 14:1102792.
https://doi.org/10.1016/j.pcd.2024.06.013
https://doi.org/10.3389/fphar.2023.1102792
Ma, H., Lin, Y.H., Dai, L.Z., Lin, C.S., Huang, Y., & Liu, S.Y.
Guan, R., Yang, Q., Yang, X., Du, W., Li, X., & Ma, G. (2022). (2023). Efficacy and safety of GLP-1 receptor agonists versus
Efficacy and safety of tirzepatide in patients with type 2 SGLT-2 inhibitors in overweight/obese patients with or
diabetes mellitus: A Bayesian network meta-analysis. without diabetes mellitus: A systematic review and network
Frontiers in Pharmacology, 13:998816. meta-analysis. BMJ Open, 13(3):e061807.
https://doi.org/10.3389/fphar.2022.998816 https://doi.org/10.1136/bmjopen-2022-061807
Haddad, F., Dokmak, G., Bader, M., & Karaman, R. (2023). McCoy, R.G., Van Houten, H.K., Deng, Y., Mandic, P.K., Ross,
A comprehensive review on weight loss associated with anti- J.S., Montori, V.M., et al. (2021). Comparison of diabetes
diabetic medications. Life (Basel), 13(4):1012. medications used by adults with commercial insurance vs
https://doi.org/10.3390/life13041012 medicare advantage, 2016 to 2019. JAMA Network Open,
4(2):e2035792.
Hu, K., Huang, H., Li, H., Wei, Y., & Yao, C. (2023). Legume-
derived bioactive peptides in type 2 diabetes: Opportunities https://doi.org/10.1001/jamanetworkopen.2020.35792

Volume 3 Issue 3 (2025) 30 https://doi.org/10.36922/ghes.8547